Pityriasis versicolor
diseaseOn this page
Also known as infections, Malassezia furfurMalassezia furfur infectiontinea versicolor
Summary
Pityriasis versicolor (MONDO:0005915) is a disease and 15 clinical trials. Top therapeutic interventions include ketoconazole, levoketoconazole, and fluconazole. A subtype of tinea infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 15
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pityriasis versicolor |
| Mondo ID | MONDO:0005915 |
| EFO | EFO:0007439 |
| MeSH | D014010 |
| DOID | DOID:9060 |
| ICD-10-CM | B36.0 |
| ICD-11 | 67108853 |
| NCIT | C82981 |
| SNOMED CT | 56454009 |
| UMLS | C0040262 |
| MedGen | 11826 |
| Is cancer (heuristic) | no |
Also known as: infections, Malassezia furfur · Malassezia furfur infection · tinea versicolor
Disease family
This is a subtype of tinea infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › tinea infection › pityriasis versicolor
Related subtypes (8): otomycosis, conidiobolomycosis, cutaneous candidiasis, dermatophytosis, eumycotic mycetoma, tinea favosa, deep seated dermatophytosis, fungal infection of the toenail
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Itraconazole.
Clinical trials & evidence
Clinical trials
Clinical trials: 15.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 6 |
| PHASE2 | 3 |
| PHASE1 | 3 |
| Not specified | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06922344 | PHASE4 | RECRUITING | Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor |
| NCT07333170 | PHASE4 | NOT_YET_RECRUITING | Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor. |
| NCT07471178 | PHASE4 | NOT_YET_RECRUITING | Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor |
| NCT00830388 | PHASE4 | COMPLETED | Ketoconazole Foam 2% for the Treatment of Versicolor |
| NCT04007237 | PHASE4 | COMPLETED | The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial |
| NCT06170333 | PHASE4 | COMPLETED | 8% Sulphur-Aloe Vera Soap as an Adjuvant Treatment for Pityriasis Versicolor |
| NCT07331792 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor |
| NCT04110834 | PHASE2 | COMPLETED | Clinical Assessment of Itraconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel |
| NCT04110860 | PHASE2 | COMPLETED | Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel |
| NCT04937920 | PHASE2 | COMPLETED | A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor |
| NCT05730244 | PHASE1 | RECRUITING | A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor |
| NCT05862714 | PHASE1 | COMPLETED | Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor |
| NCT06305637 | PHASE1 | COMPLETED | A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. |
| NCT04769804 | Not specified | UNKNOWN | Gene Polymorphism in Tinea Versicolor |
| NCT05067699 | Not specified | UNKNOWN | Vitamin D Level in Recurrent PV |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| KETOCONAZOLE | 4 | 3 |
| LEVOKETOCONAZOLE | 4 | 3 |
| FLUCONAZOLE | 4 | 1 |
| ITRACONAZOLE | 4 | 1 |
| CHEMBL328863 | 0 | 3 |
| CHEMBL75 | 0 | 3 |
| HYOSCYAMINE | -1 | 1 |